March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Fenretinide Prevents Retinal Neovascularization in Mouse Models of Angiogenesis
Author Affiliations & Notes
  • Brian C. Oveson
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland
  • Takeshi Iwase
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland
  • Sean Hackett
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland
  • Christopher Seidel
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland
  • Nathan L. Mata
    Research, ReVision Therapeutics, La Jolla, California
  • Peter A. Campochiaro
    Ophthalmology, Johns Hopkins University, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Brian C. Oveson, None; Takeshi Iwase, None; Sean Hackett, None; Christopher Seidel, None; Nathan L. Mata, None; Peter A. Campochiaro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2994. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Brian C. Oveson, Takeshi Iwase, Sean Hackett, Christopher Seidel, Nathan L. Mata, Peter A. Campochiaro; Fenretinide Prevents Retinal Neovascularization in Mouse Models of Angiogenesis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2994. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the effects of fenretinide treatment in mouse models of choroidal and retinal neovascularization (NV).

Methods: : Four week-old C57Bl/6 mice received either fenretinide-supplemented or control diet for four weeks before and 2 weeks after rupture of Bruch’s membrane by laser photocoagulation and then the area of choroidal neovascularization (CNV) at rupture sites was measured. Pregnant C57Bl/6 mice were given fenretinide-supplemented or control diet starting 1 week before giving birth. Oxygen-induced ischemic retinopathy was induced in the pups and the area of retinal NV was measured at P17. Pregnant rho/VEGF mice were given fenretinide-supplemented or control diet starting 1 week before giving birth. At P28, the pups were perfused with fluorescein-labeled dextran and the area of NV per retina was measured.

Results: : Compared to controls, fenretinide-treated mice had a significant reduction in the area of CNV at Bruch’s membrane rupture sites (0.003+0.0004 vs 0.006+0.0009 mm2; p<0.002). Fenretinide-treated mice also had a significant reduction in ischemia-induced retinal NV (0.012+0.004 vs 0.032+0.003 mm2; p<0.001). This was associated with a significant reduction in the number of macrophages in ischemic retina. In rho/VEGF transgenic mice, fenretinide treatment significantly reduced the area of subretinal NV per eye (0.004+0.0009 vs 0.018+0.003 mm2; p<0.001).

Conclusions: : Fenretinide reduces macrophage influx into the retina and suppresses retinal and choroidal NV.

Keywords: retinal neovascularization • choroid: neovascularization • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×